Determination of skeletal tumor burden on 18F-fluoride PET/CT

Journal of Nuclear Medicine

Volumn 56, Issue 10, 2015, Pages 1507-1512

  Rohren, Eric M ^a   Etchebehere, Elba C ^a,b   Araujo, John C ^a   Hobbs, Brian P ^a   Swanston, Nancy M ^a   Everding, Michael ^a   Moody, Tracy ^a   Macapinlac, Homer A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Bone metastases; Fluoride PET CT; NaF PET CT; Prostate cancer; Skeletal tumor burden

Indexed keywords

FLUORINE 18; PROSTATE SPECIFIC ANTIGEN; SODIUM FLUORIDE; FLUORINE; RADIOPHARMACEUTICAL AGENT;

AGED; ARTICLE; BONE METASTASIS; BONE TUMOR; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DOSIMETRY; FEMALE; FEMUR; HUMAN; ILIAC BONE; ISOTOPE LABELING; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REPRODUCIBILITY; SACRUM; TUMOR VOLUME; VOLUMETRY; MIDDLE AGED; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RETROSPECTIVE STUDY; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SKELETON; WHOLE BODY IMAGING;

AGED; BONE NEOPLASMS; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SKELETON; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TUMOR BURDEN; WHOLE BODY IMAGING;

EID: 84938846629     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.156026     Document Type: Article

References (34)

1. Mohler JL, Kantoff PW, Armstrong AJ, et al. Prostate cancer, version 2.2014. J Natl Compr Canc Netw. 2014;12:686-718.
2. 18F]fluorodeoxy-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial. J Clin Oncol. 2013;31:3823-3830.
3. 18F-FDG PET/CT has a high impact on patient management and provides powerful prognostic stratification in the primary staging of esophageal cancer: a prospective study with mature survival data. J Nucl Med. 2012;53:864-871.
4. 18F-FDG PET/CT in patients with mature T-cell and natural killer cell lymphomas. J Nucl Med. 2013;54:507-515.
5. 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. J Nucl Med. 2002;43:46-55.
6. 223Ra-chloride (Alpharadin). EJNMMI Res. 2011;1:4.
7. Fizazi K, Massard C, Smith M, et al. Bone-related parameters are the main prognostic factors for overall survival in men with bone metastases from castration-resistant prostate cancer. Eur Urol. 2014;68:42-50.
8. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307-310.
9. Zhang H, Wroblewski K, Pu Y. Prognostic value of tumor burden measurement using the number of tumors in non-surgical patients with non-small cell lung cancer. Acta Radiol. 2012;53:561-568.
10. 18F-FDG PET in surgical patients with non-small-cell lung cancer. Acad Radiol. 2013;20:32-40.
11. Chen HHW, Chiu N-T, Su W-C, Guo H-R, Lee B-F. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer. Radiology. 2012;264:559-566.
12. 18f-fluorodeoxyglucose positron emission tomography/computed tomography is a prognostic factor in patients with small cell lung cancer. Cancer Res Treat. 2014;46:165-171.
13. 18F-FDG PET: feasibility of a metabolic grading system. J Nucl Med. 2014;55:1260-1266.
14. 18F-FDG PET/CT in patients with extranodal NK/T-cell lymphoma. Eur J Nucl Med Mol Imaging. 2013;40:1321-1329.
15. 18F-FDG PET/CT for the prediction of outcome in patients with multiple myeloma. J Nucl Med. 2012;53:1829-1835.
16. 18F-FDG PET/CT parameters with survival in malignant pleural mesothelioma. Eur J Nucl Med Mol Imaging. 2014;41:276-282.
17. Basu S, Saboury B, Torigian DA, Alavi A. Current evidence base of FDG-PET/CT imaging in the clinical management of malignant pleural mesothelioma: emerging significance of image segmentation and global disease assessment. Mol Imaging Biol. 2011;13:801-811.
18. 18F]fluorodeoxyglucose positron emission tomography in pediatric Hodgkin's lymphoma: analysis of a prospective multicenter trial. J Clin Oncol. 2009;27:4385-4391.
19. 18F-FDG PET/CT predicts survival in patients with inflammatory breast cancer undergoing neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2013;40:1809-1816.
20. Javeri H, Xiao L, Rohren E, et al. The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma. Cancer. 2009;115:5184-5192.
21. Juweid ME, Wiseman GA, Vose JM, et al. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol. 2005;23:4652-4661.
22. Soloway MS, Hardeman SW, Hickey D, et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer. 1988;61:195-202.
23. Sabbatini P, Larson SM, Kremer A, et al. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol. 1999;17:948-957.
24. Imbriaco M, Larson SM, Yeung HW, et al. A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index. Clin Cancer Res. 1998;4:1765-1772.
25. Ulmert D, Kaboteh R, Fox JJ, et al. A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index. Eur Urol. 2012;62:78-84.
26. 18F-fluoride PET in patients with known prostate cancer: initial results from the National Oncologic PET Registry. J Nucl Med. 2014;55:574-581.
27. 99mTc-methylene diphosphonate. Semin Nucl Med. 2001;31:28-49.
28. Schiepers C, Nuyts J, Bormans G, et al. Fluoride kinetics of the axial skeleton measured in vivo with fluorine-18-fluoride PET. J Nucl Med. 1997;38:1970-1976.
29. 18F-fluoride-PET/CT is highly effective for excluding bone metastases even in patients with equivocal bone scintigraphy. Eur J Nucl Med Mol Imaging. 2012;39:1730-1736.
30. 18F-fluoride-PET/CT. J Nucl Med. 2006;47:287-297.
31. 18F PET. J Nucl Med. 1999;40:1623-1629.
32. 18F-sodium fluoride PET/CT in oncology: an atlas of SUVs. Clin Nucl Med. 2015;40:e228-e231.
33. 18F-sodium fluoride for oncology using current PET camera technology. J Nucl Med. 2012;53:1175-1184.
34. 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687. J Nucl Med. 2015;56:354-360.